8-K: Eledon Reports Q2 2025 Results, Restates Past Financials

Eledon Pharmaceuticals reported its second quarter 2025 operating and financial results, highlighted positive clinical data for tegoprubart, and announced a restatement of previously issued financial statements due to an accounting error.

Summary

• Eledon Pharmaceuticals reported a net loss of $11.2 million, or $0.13 per basic common share, for the second quarter of 2025.
• Cash, cash equivalents, and short-term investments totaled $107.6 million as of June 30, 2025, with an expected cash runway to the end of 2026.
• Updated data from the Phase 1b open-label trial for tegoprubart in kidney transplant patients showed a mean 12-month eGFR of approximately 68 mL/min/1.73 m2, which is higher than the typical 53 mL/min/1.73 m2 for standard of care.
• The company is on track to report topline results from its Phase 2 BESTOW trial in kidney transplantation in November 2025.
• Management and the Audit Committee concluded that previously issued financial statements for fiscal years 2023 and 2024, and interim periods in 2024 and Q1 2025, are materially misstated and should no longer be relied upon.
• The misstatement is due to an incorrect classification of Series X and Series X-1 non-voting convertible preferred stock as permanent equity instead of temporary equity.
• The identified accounting errors did not impact the company's cash, short-term investment position, liquidity, or results of operations.
• A material weakness in internal control over financial reporting related to equity instruments was identified, leading to a conclusion that internal controls were not effective as of December 31, 2024, and disclosure controls were not effective for several periods in 2024 and Q1 2025.
• The company intends to file amendments to its 2024 Form 10-K and 2025 Form 10-Q to restate the impacted financial statements.

Sentiment

Score: 5

Explanation: The sentiment is mixed. Positive clinical trial data for tegoprubart and a solid cash runway provide strong upside potential. However, the material misstatement of past financial statements and the identified material weakness in internal controls are significant negative factors that could impact investor confidence and introduce uncertainty regarding financial reporting integrity.

Positives

• Tegoprubart demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 in Phase 1b kidney transplant patients, outperforming the standard of care's typical 53 mL/min/1.73 m2.
• Tegoprubart continues to be well tolerated in the Phase 1b trial with no cases of death, graft loss, drug-related tremor, sepsis, or new-onset diabetes.
• The company is on track to report topline results from the Phase 2 BESTOW trial in kidney transplantation in November 2025.
• Three islet cell transplant recipients achieved insulin independence in an investigator-initiated trial evaluating tegoprubart.
• Preclinical data in liver allotransplantation utilizing tegoprubart demonstrated markedly prolonged graft survival in non-human primates.
• Eledon was added to the Russell 3000 and Russell 2000 Indexes in June 2025, broadening investor visibility.
• Cash, cash equivalents, and short-term investments of $107.6 million as of June 30, 2025, are expected to fund operations to the end of 2026.

Negatives

• Previously issued audited consolidated financial statements for fiscal years ended December 31, 2024 and 2023, and unaudited condensed consolidated financial statements for interim periods in 2024 and Q1 2025, are materially misstated and should no longer be relied upon.
• A material weakness in internal control over financial reporting related to accounting for equity instruments was identified.
• Internal control over financial reporting was not effective as of December 31, 2024.
• Disclosure controls and procedures were not effective as of March 31, 2024, June 30, 2024, September 31, 2024, December 31, 2024, and March 31, 2025.

Risks

• A material weakness in internal control over financial reporting related to accounting for equity instruments has been identified, which could impact the reliability of future financial reporting.
• Risks relating to the safety and efficacy of drug candidates, including tegoprubart, remain inherent in clinical development.
• Clinical development timelines are subject to risks, including interactions with regulators, clinical site operations, and patient enrollment.
• Costs of clinical trials and the sufficiency of capital resources to fund planned clinical trials pose financial risks.
• Actual results may differ materially from forward-looking statements due to various factors, including those discussed in SEC filings.

Future Outlook

The company anticipates reporting topline results from its Phase 2 BESTOW trial in kidney transplantation in November 2025. Additionally, it plans to launch an investigator-initiated trial at Massachusetts General Hospital (MGH) to induce donor-specific immune tolerance and enroll three more patients in the University of Chicago Medicine islet cell transplant trial. Current cash, cash equivalents, and short-term investments are expected to fund operations until the end of 2026.

Management Comments

• "We are proud to enter the second half of the year with strong momentum as we have achieved all of our key milestones to date including advancing tegoprubart in kidney, islet cell (type 1 diabetes), and liver allotransplantation, as well as in xenotransplantation."
• "The positive data we recently presented at the World Transplant Congress reinforce the potential of tegoprubart to improve long-term transplant outcomes while reducing the toxic side effects often associated with the current standard of care."
• "With these encouraging results in hand, we look forward to sharing topline data later this year from our Phase 2 BESTOW trial in kidney transplantation and to continuing to explore tegoprubart's broad potential in other transplant indications."

Industry Context

Eledon Pharmaceuticals is developing tegoprubart, an anti-CD40L antibody, which targets a well-validated biological pathway central to both adaptive and innate immune cell activation. This positions it as a promising immunomodulatory therapeutic intervention for various transplant indications. The reported Phase 1b data showing superior eGFR outcomes compared to calcineurin inhibitor-based standard of care suggests a potential paradigm shift in immunosuppression, aiming to reduce toxicity and improve long-term graft survival, which are critical unmet needs in the transplant field.

Comparison to Industry Standards

• Tegoprubart's mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for kidney patients in its Phase 1b trial compares favorably to historical studies using the standard of care, calcineurin inhibitor-based immunosuppression therapy, which typically report aggregate mean eGFRs of approximately 53 mL/min/1.73 m2 at 12 months after kidney transplant.
• The observed tolerability profile of tegoprubart, with no cases of death, graft loss, drug-related tremor, sepsis, or new-onset diabetes, suggests a potentially improved safety profile compared to current immunosuppressive regimens known for significant side effects.

Corporate Governance

Stakeholder Impact

• Shareholders: Will be impacted by the restatement of past financial statements, which may affect confidence and stock valuation. However, positive clinical data could provide long-term value.
• Patients: Potential beneficiaries of tegoprubart's development, offering improved outcomes and reduced side effects in organ and cell transplantation.
• Regulatory Authorities: The SEC will oversee the restatement process and the remediation of the identified material weakness in internal controls.

Next Steps

• Report topline results from the Phase 2 BESTOW trial of tegoprubart in kidney transplantation in November 2025.
• Launch an investigator-initiated trial at MGH evaluating tegoprubart to induce donor-specific immune tolerance through mixed chimerism.
• Enroll three additional patients in the investigator-led clinical trial at UChicago Medicine for subjects with type 1 diabetes treated with tegoprubart for pancreatic islet transplant rejection.
• File amendments to the 2024 Form 10-K and 2025 Form 10-Q to restate consolidated financial statements.

Key Dates

Recommendation

The positive clinical data for tegoprubart, particularly the superior eGFR results compared to standard of care and the successful islet cell transplants, demonstrate strong therapeutic potential and pipeline progress. The company also has a solid cash runway into late 2026. However, the material misstatement of previously issued financial statements and the identified material weakness in internal controls over financial reporting are significant concerns that undermine investor confidence and introduce uncertainty. While the errors did not impact cash or liquidity, the need for restatement and the control deficiencies warrant caution. Investors should hold to monitor the restatement process, the remediation of internal controls, and the upcoming Phase 2 BESTOW trial results in November 2025 before making further investment decisions.

Keywords

Eledon Pharmaceuticals, ELDN, tegoprubart, kidney transplant, islet cell transplant, xenotransplantation, CD40L, financial restatement, accounting error, material weakness, Q2 2025 results, biotechnology, clinical trial, eGFR, immunosuppression, SEC filing